All
Reblozyl Continues to Improve MDS Transfusion Independence
Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.
Experiencing a Type of Breast Cancer Déjà Vu
After a good friend told me about her recent diagnosis of breast cancer, I started experiencing a type of breast cancer déjà vu.
An Expert Breakdown of SurVaxM, the Novel Brain Cancer Vaccine
SurVaxM, which is being studied in gliobastoma, targets a certain protein that is found on the brain cancer cells.
Safety Profile of Lower-Dose Oral Onureg Remains Consistent in Lower-Risk MDS
The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.
Enhertu Boosts PFS in Pretreated, HR-Positive, HER2-Low and -Ultralow Breast Cancer
Enhertu lengthened the time to progression in patients with HR-positive, HER2-low or -ultralow metastatic breast cancer.
Chemo, Targeted Drugs Extremely Efficacious in HER2-Positive Breast Cancer
Presurgical paclitaxel, Herceptin and Perjeta showed “incredible efficacy” in treatment of HER2-positive breast cancer.
Perioperative Chemo Shows Longer Survival in Esophageal Cancer
Perioperative chemotherapy with chemotherapy led to improved survival outcomes versus neoadjuvant chemoradiation in resectable esophageal cancer.
Blenrep Combo Lengthens Time to Progression in Relapsed, Refractory Myeloma
Blenrep, Pomalyst and dexamethasone improved progression-free survival compared to Velcade, Pomalyst and dexamethasone in patients with relapsed/refractory myeloma.
Neoadjuvant Opdivo Plus Yervoy Provides ‘Excellent Responses’ in Stage 3 Melanoma
Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care.
Tagrisso Could Become Standard of Care for Some With EGFR+ NSCLC
Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer.
Lymphadenectomy Didn’t Improve Progression, Survival in Ovarian Cancer
Researchers found that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival among patients with advanced ovarian cancer.
Palliative Care via Telehealth Similarly Beneficial to Quality of Life in Lung Cancer
Researchers found telehealth care to deliver comparable quality-of-life benefits versus in-person visits among patients with advanced non-small cell lung cancer.
Posttreatment Imfinzi Sets New Standard for Small Cell Lung Cancer
For the first time in decades, a new regimen — consolidation Imfinzi after chemoradiation — improved outcomes in patients with limited-stage small cell lung cancer.
Rybrevant Plus Leclaza Has ‘Very Potent Activity’ in Lung Cancer Subset
Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.
Long-Term Follow-Up Still Shows Tafinlar/Mekinist Benefit in Melanoma
Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.
Rybrevant Plus Leclaza May Be New Standard for EGFR-Mutant Lung Cancer
Rybrevant plus Leclaza outperformed Tagrisso regarding progression-free survival in patients with EGFR-mutant non-small cell lung cancer.
Adcetris Regimen Outperforms Intense Chemo in Classical Hodgkin Lymphoma
An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.
The Miracle Workers of Cancer
When a group of people told me my non-Hodgkin lymphoma cure was a miracle, I realized it was only made possible because of health care professionals.
Lorbrena Shows Longest Progression-Free Survival in Advanced NSCLC
Lorbrena demonstrated longer progression-free survival and improved time to intracranial progression, compared with Xalkori in ALK-positive non-small cell lung cancer.
Bill Walton Dies, Ancient Skull Shows Evidence of Cancer Surgery and More
From NBA Hall of Famer Bill Walton dying from cancer to an ancient skull showing evidence of early cancer treatments, here’s what’s happening in the oncology space this week.
Positive Scemblix Data ‘May Change the Treatment Paradigm in CML’
Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Inavolisib Combo Gets FDA Priority Review in HR-Positive, HER2-Negative Breast Cancer
The priority review is based on findings from a study that found that inavolisib reduced the risk for disease progression or death by 57%.
Colon Cancer Helped Me Become Who I Am Today
After I had surgery for my colon cancer, I started taking better care of myself, starting with regaining weight.
FDA Approves Breyanzi for Relapsed, Refractory MCL
The CAR-T cell therapy, Breyanzi, has received FDA approval for relapsed or refractory mantle cell lymphoma.
Laparoscopic Liver Surgery Led to Faster Recovery, Earlier Subsequent Treatment
Compared to open hemihepatectomy, the laparoscopic approach resulted in faster recovery time and higher quality of life, researchers found.
Cancer Survivorship Helped Me Be Kinder to Myself
I expected chemotherapy, radiation and surgery to be difficult, but I felt totally lost after treatment ended.
My Interesting Cancer Advocacy Group
As someone with follicular lymphoma, I joined a cancer advocacy group, but it wasn't what I was expecting.
FDA Approves Retevmo for RET-Positive Pediatric Cancers
Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions.
FDA Grants Priority Review to Sarclisa for Multiple Myeloma
Sarclisa was granted a priority review by the Food and Drug Administration for patients newly diagnosed with multiple myeloma who are ineligible for blood transplants.
How Monica Took an Active Role in Her Breast Cancer Treatment Journey
